LE WE PMID CA
Alzheimer s disease114Alzheimer Erkrankung

27 Hydroxycholesterol

Aids

Aluminum

Alzheimer s disease

Amygdala

Amyloid angiopathy

Amyloid precursor protein

Amyloidosis

Amyotrophic lateral sclerosis

Antibodies (catalytic)

Antiinflammatory compounds

Apolipoprotein E4

Aripiprazole

Autophagy

BACE1

Bapineuzumab ttAmyloidBeta

Beclin1

Biomarker (BASKET)

Biomembranes (BASKET)

Borreliosis

CNS (MRS)

CNS (MRT)

CNS (PET)

CNS (Stroke BASKET)

Cystatin C

Dementia (frontotemporal)

Donepezil

ERS UFR (Toxikologie)

Frontotemporal lobar degeneration

GADD153 CHOP

Galantamine

gamma Secretase

Genetics (Gene expression endophenotype)

History of medicine

Imaging (Molecular)

Insulin degrading enzyme

Kluver Bucy syndrome

Leptin

Lewy body

Lipid peroxide

Lipid rafts and membrane microdomains

LRP1

Maillard reaction

Melatonin

Memantine

MGAT3

Mitochondria (BASKET)

Mitochondria (Dysfunction)

Mitochondria (Mitochondriopathy)

Mitophagy

MRT (functional fMRT)

Multiple sclerosis

NADPH oxidase

Nervous system (Neurodegeneration)

Neuron (BASKET)

Neurovascular unit

Niemann Pick s disease C

Paradontosis

Parkinson s disease

Pin1

Prions and associated diseases

Retinoids

Rivastigmin

Septum (Neurophysiology)

Sirtuin

SORL1

Spirochaete

Statin

Structure det. tissue level to single molecule localization

Sulfatides

Synuclein

TDP43

Testosterone

Tissue transglutaminase

Treponemas

2005  
1
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
[16081444] BMJ 331(7512): 321-7 (2005)
2005  
2
Treatments for Alzheimer disease.
[16004170] South Med J 98(6): 628-35 (2005)
2001  
3
Biological and genetic markers of sporadic Alzheimer's disease.
[11332200] Acta Med Okayama 55(2): 55-63 (2001)
2009  
4
Mitochondrial Drugs for Alzheimer Disease.
[20657666] Pharmaceuticals (Basel) 2(3): 287-298 (2009)
1999  
5
Diagnosis, management, and treatment of Alzheimer disease: a guide for the internist.
[10219924] Arch Intern Med 159(8): 789-98 (1999)
1997  
6
The genetics and pathophysiology of Alzheimer's disease.
[9366805] J Intern Med 242(4): 281-4 (1997)
2009  
7
Alzheimer disease: time to improve its diagnosis and treatment.
[19122111] Cleve Clin J Med 76(1): 49-58 (2009)
2008  
8
Insular Alzheimer disease pathology and the psychometric correlates of mortality.
[18540156] Cleve Clin J Med 75 Suppl 2(): S97-9 (2008)
2008  
9
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
[18686744] Clin Interv Aging 3(2): 211-25 (2008)
2007  
10
Pathogenesis of Alzheimer's disease.
[18044185] Clin Interv Aging 2(3): 347-59 (2007)
2007  
11
Rivastigmine in the treatment of Alzheimer's disease: an update.
[18044073] Clin Interv Aging 2(1): 17-32 (2007)
2007  
12
Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease.
[18020111] Can J Psychiatry 52(10): 630-46 (2007)
2007  
13
Pharmacotherapy of Alzheimer disease.
[18020110] Can J Psychiatry 52(10): 620-9 (2007)
2007  
14
Trials and tribulations of evidence-based medicine: the case of Alzheimer disease therapeutics.
[18020109] Can J Psychiatry 52(10): 617-9 (2007)
2004  
15
GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.
[15362248] Can J Psychiatry 49(7): 439-53 (2004)
2007  
16
Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.
[17599166] Prim Care Companion J Clin Psychiatry 9(1): 32-41 (2007)
1999  
17
The neurobiology and pharmacotherapy of Alzheimer's disease.
[9990552] J Neuropsychiatry Clin Neurosci 11(1): 19-31 (1999)
2000  
18
Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type.
[11145458] Psychiatry Clin Neurosci 54(6): 611-20 (2000)
2001  
19
Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges.
[11390632] Learn Mem 8(3): 121-33 (2001)
2009  
20
Update on the use of memantine in Alzheimer's disease.
[19557118] Neuropsychiatr Dis Treat 5(): 237-47 (2009)
2008  
21
Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review.
[18830441] Neuropsychiatr Dis Treat 4(3): 549-55 (2008)
2007  
22
Memantine: efficacy and safety in mild-to-severe Alzheimer's disease.
[19300557] Neuropsychiatr Dis Treat 3(2): 245-58 (2007)
2007  
23
Progress update: Pharmacological treatment of Alzheimer's disease.
[19300586] Neuropsychiatr Dis Treat 3(5): 569-78 (2007)
2006  
24
Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis.
[17015224] Neuron 52(1): 15-31 (2006)
2006  
25
A hundred years of Alzheimer's disease research.
[17015223] Neuron 52(1): 3-13 (2006)
2004  
26
Deciphering the molecular basis of memory failure in Alzheimer's disease.
[15450169] Neuron 44(1): 181-93 (2004)
1996  
27
Mechanisms of neuronal degeneration in Alzheimer's disease.
[8630250] Neuron 16(5): 921-32 (1996)
2009  
28
The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease.
[19393022] J Neurochem 109 Suppl 1(): 153-9 (2009)
2007  
29
Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics.
[17986152] J Neurochem 103 Suppl 1(): 171-9 (2007)
2010  
30
Tau oligomers and aggregation in Alzheimer's disease.
[19943854] J Neurochem 112(6): 1353-67 (2010)
2009  
31
Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease.
[20050287] J Neurochem 111(6): 1275-308 (2009)
2009  
32
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.
[19457065] J Neurochem 110(4): 1129-34 (2009)
2007  
33
Alzheimer's disease: the lipid connection.
[17986151] J Neurochem 103 Suppl 1(): 159-70 (2007)
2006  
34
Alois Alzheimer and Alzheimer's disease: a centennial perspective.
[17076655] J Neurochem 99(3): 708-10 (2006)
2006  
35
Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
[16787410] J Neurochem 98(4): 993-1006 (2006)
2006  
36
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.
[16805778] J Neurochem 97(6): 1700-25 (2006)
2006  
37
Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease.
[16405497] J Neurochem 96(3): 609-23 (2006)
2006  
38
Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease.
[16305625] J Neurochem 96(1): 1-13 (2006)
2006  
39
Neuronal protection by sirtuins in Alzheimer's disease.
[16219030] J Neurochem 96(2): 305-13 (2006)
2004  
40
Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action.
[15485484] J Neurochem 91(3): 521-36 (2004)
2004  
41
A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade.
[15485483] J Neurochem 91(3): 513-20 (2004)
2003  
42
Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration.
[12950441] J Neurochem 86(6): 1313-27 (2003)
1999  
43
Alzheimer's disease and the amyloid beta protein: What is the role of amyloid?
[10428038] J Neurochem 73(2): 443-9 (1999)
1997  
44
An etiological role of amyloidogenic carboxyl-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease.
[9109502] J Neurochem 68(5): 1781-91 (1997)
2009  
45
Mechanism-based treatments for Alzheimer's disease.
[19585951] Dialogues Clin Neurosci 11(2): 159-69 (2009)
2009  
46
2009  
47
Biological markers for early detection and pharmacological treatment of Alzheimer's disease.
[19585950] Dialogues Clin Neurosci 11(2): 141-57 (2009)
2009  
48
Novel strategies for the prevention of dementia from Alzheimer's disease.
[19585948] Dialogues Clin Neurosci 11(2): 129-34 (2009)
2009  
49
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention.
[19585947] Dialogues Clin Neurosci 11(2): 111-28 (2009)
2007  
50
Frontotemporal dementia to Alzheimer's disease.
[17726914] Dialogues Clin Neurosci 9(2): 153-60 (2007)
2003  
51
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
[14530799] CNS Drug Rev 9(3): 275-308 (2003)
2002  
52
Imaging amyloid-beta deposits in vivo.
[12218409] J Cereb Blood Flow Metab 22(9): 1035-41 (2002)
2009  
53
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.
[20076796] J Clin Neurol 5(4): 153-66 (2009)
2007  
54
The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.
[18201952] Neurotox Res 12(4): 247-62 (2007)
2007  
55
Glial cell dysregulation: a new perspective on Alzheimer disease.
[18201950] Neurotox Res 12(4): 215-32 (2007)
2002  
56
Involvement of Maillard reactions in Alzheimer disease.
[12829400] Neurotox Res 4(3): 191-209 (2002)
2003  
57
The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
[12805474] J Pharmacol Exp Ther 306(3): 821-7 (2003)
2009  
58
Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.
[19293145] Pharmacol Rev 61(1): 39-61 (2009)
2002  
59
Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease.
[12223532] Pharmacol Rev 54(3): 469-525 (2002)
1997  
60
From molecular structure to Alzheimer therapy.
[9268083] Jpn J Pharmacol 74(3): 225-41 (1997)
2006  
61
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
[16409879] Health Technol Assess 10(1): iii-iv, ix-xi, 1-160 (2006)
1999  
62
Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity.
[10204569] J Leukoc Biol 65(4): 416-27 (1999)
1999  
63
Inflammation of the brain in Alzheimer's disease: implications for therapy.
[10204568] J Leukoc Biol 65(4): 409-15 (1999)
2008  
64
Alzheimer's disease is type 3 diabetes-evidence reviewed.
[19885299] J Diabetes Sci Technol 2(6): 1101-13 (2008)
2005  
65
Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease.
[15933761] Acta Biochim Pol 52(2): 417-23 (2005)
2000  
66
Alzheimer's disease: its origin at the membrane, evidence and questions.
[11310972] Acta Biochim Pol 47(3): 725-33 (2000)
2010  
67
Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease.
[20567751] Mol Biosyst 6(10): 1760-6 (2010)
2009  
68
Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease.
[19156258] Mol Biosyst 5(2): 134-42 (2009)
2001  
69
Molecular and cell biological aspects of Alzheimer disease.
[11721879] J Hum Genet 46(11): 609-18 (2001)
1996  
70
Biological markers for the clinical diagnosis of Alzheimer's disease.
[8875763] Tohoku J Exp Med 179(2): 65-79 (1996)
1994  
71
Alzheimer's disease and beta-amyloid.
[7761982] Tohoku J Exp Med 174(3): 181-303, A1-3 (1994)
1994  
72
Inflammatory response in Alzheimer's disease.
[7539162] Tohoku J Exp Med 174(3): 295-303 (1994)
2006  
73
Alzheimer's disease: psychopathology, medical management and dental implications.
[16946428] J Am Dent Assoc 137(9): 1240-51 (2006)
2005  
74
Fatty acid oxidation in the pathogenesis of Alzheimer's disease.
[15855630] Am J Pathol 166(5): 1283-9 (2005)
1996  
75
The Golgi apparatus and the pathogenesis of Alzheimer's disease.
[8579097] Am J Pathol 148(2): 355-60 (1996)
2007  
76
Mitoenergetic failure in Alzheimer disease.
[16807300] Am J Physiol Cell Physiol 292(1): C8-23 (2007)
2004  
77
Alzheimer disease: mechanistic understanding predicts novel therapies.
[15096334] Ann Intern Med 140(8): 627-38 (2004)
2003  
78
Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies.
[12614093] Ann Intern Med 138(5): 400-10 (2003)
2008  
79
Retromer sorting: a pathogenic pathway in late-onset Alzheimer disease.
[18332244] Arch Neurol 65(3): 323-8 (2008)
2006  
80
Therapeutic approaches to Alzheimer's disease.
[17018549] Brain 129(Pt 11): 2840-55 (2006)
2009  
81
The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease.
[20054780] Folia Neuropathol 47(4): 289-99 (2009)
2006  
82
Plaques and tangles and the pathogenesis of Alzheimer's disease.
[16565925] Folia Neuropathol 44(1): 1-11 (2006)
2005  
83
The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.
[15864339] J Clin Invest 115(5): 1121-9 (2005)
1999  
84
The cholinergic hypothesis of Alzheimer's disease: a review of progress.
[10071091] J Neurol Neurosurg Psychiatry 66(2): 137-47 (1999)
2004  
85
Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.
[15644984] J Psychiatry Neurosci 29(6): 427-41 (2004)
2003  
86
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.
[12587847] J Psychiatry Neurosci 28(1): 13-26 (2003)
2009  
87
Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice.
[19622825] JAMA 302(4): 436-7 (2009)
2003  
88
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
[12517232] JAMA 289(2): 210-6 (2003)
2005  
89
Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.
[16489369] NeuroRx 2(4): 612-26 (2005)
2004  
90
Biomarkers of Alzheimer disease in plasma.
[15717023] NeuroRx 1(2): 226-34 (2004)
2004  
91
Cerebrospinal fluid protein biomarkers for Alzheimer's disease.
[15717022] NeuroRx 1(2): 213-25 (2004)
2004  
92
Molecular neuroimaging in Alzheimer's disease.
[15717021] NeuroRx 1(2): 206-12 (2004)
2004  
93
Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease.
[15717020] NeuroRx 1(2): 196-205 (2004)
2004  
94
Neuroprotective strategies in Alzheimer's disease.
[15717012] NeuroRx 1(1): 117-27 (2004)
1992  
95
2002  
96
Alzheimer disease as a vascular disorder: nosological evidence.
[11935076] Stroke 33(4): 1152-62 (2002)
2004  
97
Alzheimer's disease: neuropathologic findings and recent advances in imaging.
[14684506] AJR Am J Roentgenol 182(1): 3-13 (2004)
2002  
98
Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
[12163621] J Nucl Med 43(8): 983-90 (2002)
2008  
99
Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.
[19047609] CMAJ 179(12): 1279-87 (2008)
2003  
100
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
[12975222] CMAJ 169(6): 557-64 (2003)
2000  
101
Causes of Alzheimer's disease.
[11216203] CMAJ 162(1): 65-72 (2000)
2009  
102
Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis.
[19001534] AJNR Am J Neuroradiol 30(2): 404-10 (2009)
2008  
103
Neuropathology for the neuroradiologist: plaques and tangles.
[17925367] AJNR Am J Neuroradiol 29(1): 18-22 (2008)
2010  
104
Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.
[20640545] Age (Dordr) 32(3): 365-84 (2010)
2011  
105
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.
[21211070] Alzheimers Res Ther 3(1): 1 (2011)
2011  
106
The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease.
[21639952] Alzheimers Res Ther 3(3): 20 (2011)
2010  
107
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.
[20122289] Alzheimers Res Ther 2(1): 1 (2010)
2009  
108
Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease.
[19845950] Alzheimers Res Ther 1(2): 7 (2009)
2009  
109
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease.
[19822028] Alzheimers Res Ther 1(2): 6 (2009)
2009  
110
Drug development for Alzheimer's disease: where are we now and where are we headed?
[19616185] Am J Geriatr Pharmacother 7(3): 167-85 (2009)
2011  
111
[Guidelines for the medical treatment of patients with Alzheimer's disease].
[21739387] Acta Neurol Taiwan 20(2): 85-100 (2011)
2010  
112
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.
[20652578] Acta Neuropathol 120(3): 385-99 (2010)
2010  
113
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.
[20563819] Acta Neuropathol 120(2): 131-43 (2010)
2010  
114
Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.
[20354705] Acta Neuropathol 119(5): 523-41 (2010)
2011  
115
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.
[21516511] Acta Neuropathol 121(5): 571-87 (2011)
2008  
116
TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease.
[18575875] Acta Neuropathol 116(2): 135-40 (2008)
2008  
117
Alzheimer disease models and human neuropathology: similarities and differences.
[18038275] Acta Neuropathol 115(1): 5-38 (2008)
2011  
118
Amyloid precursor protein processing and Alzheimer's disease.
[21456963] Annu Rev Neurosci 34(-): 185-204 (2011)
2010  
119
Initial experience in using continuous arterial spin-labeled MR imaging for early detection of Alzheimer disease.
[20075093] AJNR Am J Neuroradiol 31(5): 847-55 (2010)
2011  
120
Alzheimer's disease: a review of recent developments.
[21691010] Ann Afr Med 10(2): 73-9 (2011)
2008  
121
Neurobiology of apathy in Alzheimer's disease.
[18641892] Arq Neuropsiquiatr 66(2B): 436-43 (2008)
2010  
122
Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners.
[21155625] Altern Med Rev 15(3): 223-44 (2010)
2008  
123
Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.
[18590347] Altern Med Rev 13(2): 85-115 (2008)
2004  
124
Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up.
[14982829] Am J Pathol 164(3): 757-61 (2004)
2009  
125
Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease.
[19956426] Am J Transl Res 1(2): 131-47 (2009)
2010  
126
Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis.
[20452460] Biochim Biophys Acta 1801(8): 878-86 (2010)
2010  
127
Murine models of Alzheimer's disease and their use in developing immunotherapies.
[20471477] Biochim Biophys Acta 1802(10): 847-59 (2010)
2010  
128
Membrane rafts in Alzheimer's disease beta-amyloid production.
[20303415] Biochim Biophys Acta 1801(8): 860-7 (2010)
2010  
129
Intracellular cholesterol homeostasis and amyloid precursor protein processing.
[20304094] Biochim Biophys Acta 1801(8): 853-9 (2010)
2010  
130
Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships?
[20304095] Biochim Biophys Acta 1801(8): 975-82 (2010)
2010  
131
Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.
[19619643] Biochim Biophys Acta 1802(1): 11-9 (2010)
2010  
132
Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.
[20176130] Biochim Biophys Acta 1801(8): 924-9 (2010)
2007  
133
Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm.
[17553456] Biochim Biophys Acta 1768(8): 1966-75 (2007)
2007  
134
Dysfunction of amyloid precursor protein signaling in neurons leads to DNA synthesis and apoptosis.
[17113271] Biochim Biophys Acta 1772(4): 430-7 (2007)
2007  
135
Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease.
[17215111] Biochim Biophys Acta 1772(4): 438-45 (2007)
2007  
136
Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism?
[17317113] Biochim Biophys Acta 1772(4): 422-9 (2007)
2009  
137
Relevance of transgenic mouse models to human Alzheimer disease.
[18948253] J Biol Chem 284(10): 6033-7 (2009)
2009  
138
Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure.
[18948255] J Biol Chem 284(10): 6027-31 (2009)
2010  
139
Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy.
[20838046] Dement Geriatr Cogn Disord 30(2): 161-78 (2010)
2008  
140
Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease.
[18931498] Dement Geriatr Cogn Disord 26(4): 384-90 (2008)
2011  
141
Modes of Aβ toxicity in Alzheimer's disease.
[21706148] Cell Mol Life Sci 68(20): 3359-75 (2011)
2010  
142
Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process.
[20393191] Physiol Rev 90(2): 465-94 (2010)
2009  
143
Reassessing the amyloid cascade hypothesis of Alzheimer's disease.
[19124085] Int J Biochem Cell Biol 41(6): 1261-8 (2009)
2004  
144
Contribution of cerebral amyloid angiopathy to Alzheimer's disease.
[14707293] J Neurol Neurosurg Psychiatry 75(1): 1-4 (2004)
2007  
145
Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review.
[17371908] J Neurol Neurosurg Psychiatry 78(9): 917-28 (2007)
2010  
146
Amyloid-independent mechanisms in Alzheimer's disease pathogenesis.
[21068297] J Neurosci 30(45): 14946-54 (2010)
2010  
147
Quantitative structural MRI for early detection of Alzheimer's disease.
[20977326] Expert Rev Neurother 10(11): 1675-88 (2010)
2010  
148
Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.
[20420489] Expert Rev Neurother 10(5): 683-91 (2010)
2004  
149
Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.
[15853610] Expert Rev Neurother 4(1): 5-16 (2004)
2008  
150
Gamma-secretase modulators: hopes and setbacks for the future of Alzheimer's treatment.
[18986229] Expert Rev Neurother 8(11): 1611-3 (2008)
2008  
151
Targeting miRNAs in Alzheimer's disease.
[18986230] Expert Rev Neurother 8(11): 1615-6 (2008)
2008  
152
Cystatin C: a potential target for Alzheimer's treatment.
[18457524] Expert Rev Neurother 8(5): 687-9 (2008)
2009  
153
All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease.
[19903021] Expert Rev Neurother 9(11): 1615-21 (2009)
2010  
154
The biochemical study on the etiology of Alzheimer's disease.
[20075608] Proc Jpn Acad Ser B Phys Biol Sci 86(1): 54-61 (2010)
2010  
155
Current status on Alzheimer disease molecular genetics: from past, to present, to future.
[20388643] Hum Mol Genet 19(R1): R4-R11 (2010)
2010  
156
Molecular mechanisms of neurodegeneration in Alzheimer's disease.
[20413653] Hum Mol Genet 19(R1): R12-20 (2010)
2010  
157
Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
[20169037] Clin Interv Aging 5(-): 1-6 (2010)
2008  
158
Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole.
[18982919] Clin Interv Aging 3(3): 491-501 (2008)
2011  
159
Recent progress in understanding Alzheimer's β-amyloid structures.
[21411326] Trends Biochem Sci 36(6): 338-45 (2011)
2010  
160
Alzheimer's disease: insights from Drosophila melanogaster models.
[20036556] Trends Biochem Sci 35(4): 228-35 (2010)
2008  
161
Androgen regulation of beta-amyloid protein and the risk of Alzheimer's disease.
[17658612] Brain Res Rev 57(2): 444-53 (2008)
2008  
162
Novel therapeutics for Alzheimer's disease.
[18625448] Neurotherapeutics 5(3): 377-80 (2008)
2008  
163
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
[18625449] Neurotherapeutics 5(3): 381-90 (2008)
2008  
164
Inhibition and modulation of gamma-secretase for Alzheimer's disease.
[18625450] Neurotherapeutics 5(3): 391-8 (2008)
2008  
165
beta-Secretase as a therapeutic target for Alzheimer's disease.
[18625451] Neurotherapeutics 5(3): 399-408 (2008)
2008  
166
New therapeutic targets in the neurovascular pathway in Alzheimer's disease.
[18625452] Neurotherapeutics 5(3): 409-14 (2008)
2008  
167
Therapeutics for Alzheimer's disease based on the metal hypothesis.
[18625454] Neurotherapeutics 5(3): 421-32 (2008)
2008  
168
Mouse models of Alzheimer's dementia: current concepts and new trends.
[18818286] Endocrinology 149(12): 5952-7 (2008)
2012  
169
Endoplasmic reticulum stress-induced CHOP activation mediates the down-regulation of leptin in human neuroblastoma SH-SY5Y cells treated with the oxysterol 27-hydroxycholesterol.
[21983012] Cell Signal 24(2): 484-92 (2012)
2007  
170
Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.
[17664130] Free Radic Biol Med 43(5): 658-77 (2007)
2008  
171
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models.
[18482592] Free Radic Biol Med 45(3): 219-30 (2008)
2009  
172
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy.
[19339974] Nat Rev Neurosci 10(5): 333-44 (2009)
2011  
173
New diagnostic criteria for Alzheimer's disease.
[21861660] Biomark Med 5(4): 407-9 (2011)
2011  
174
Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease.
[21861661] Biomark Med 5(4): 411-3 (2011)
2011  
175
Delineating Alzheimer's disease progression with MGAT3, a biomarker for improved prognosis and personalized therapy.
[22003913] Biomark Med 5(5): 645-7 (2011)
2010  
176
Cerebrospinal fluid biomarkers of Alzheimer's disease.
[20361010] Biomark Med 4(1): 51-63 (2010)
2010  
177
Biomarkers of oxidative damage and inflammation in Alzheimer's disease.
[20383271] Biomark Med 4(1): 27-36 (2010)
2010  
178
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.
[20383319] Biomark Med 4(1): 3-14 (2010)
2010  
179
Biomarkers in Alzheimer's disease: past, present and future.
[20387301] Biomark Med 4(1): 15-26 (2010)
2010  
180
Blood-based biomarkers of Alzheimer's disease: challenging but feasible.
[20387303] Biomark Med 4(1): 65-79 (2010)
2009  
181
Alzheimer's mechanisms in ischemic brain degeneration.
[19943340] Anat Rec (Hoboken) 292(12): 1863-81 (2009)
2009  
182
In vivo morphological changes in animal models of amyotrophic lateral sclerosis and Alzheimer's-like disease: MRI approach.
[19943341] Anat Rec (Hoboken) 292(12): 1882-92 (2009)
2010  
183
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
[20837848] Arch Neurol 67(9): 1062-7 (2010)
2010  
184
Beclin 1 complex in autophagy and Alzheimer disease.
[20937944] Arch Neurol 67(10): 1181-4 (2010)
2009  
185
Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease.
[19901162] Arch Neurol 66(11): 1325-8 (2009)
2009  
186
Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease.
[19139311] Arch Neurol 66(1): 125-9 (2009)
2010  
187
Alzheimer disease: update on basic mechanisms.
[20926741] J Am Osteopath Assoc 110(9 Suppl 8): S3-9 (2010)
2010  
188
Investigational medications for treatment of patients with Alzheimer disease.
[20926740] J Am Osteopath Assoc 110(9 Suppl 8): S27-36 (2010)
2010  
189
Current treatments for patients with Alzheimer disease.
[20926739] J Am Osteopath Assoc 110(9 Suppl 8): S16-26 (2010)
2010  
190
Biomarkers for early detection of Alzheimer disease.
[20926738] J Am Osteopath Assoc 110(9 Suppl 8): S10-5 (2010)
2011  
191
Disease-modifying treatments for Alzheimer's disease.
[21765871] Ther Adv Neurol Disord 4(4): 203-16 (2011)
2010  
192
Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease.
[21358971] Curr Neuropharmacol 8(3): 211-7 (2010)
2010  
193
Update on the pharmacological treatment of Alzheimer's disease.
[20808547] Curr Neuropharmacol 8(1): 69-80 (2010)
2009  
194
Implication of complement system and its regulators in Alzheimer's disease.
[19721814] Curr Neuropharmacol 7(1): 1-8 (2009)
2007  
195
Current experimental therapy for Alzheimer's disease.
[18615180] Curr Neuropharmacol 5(2): 127-34 (2007)
2010  
196
Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.
[20217279] Mol Neurobiol 41(2-3): 107-14 (2010)
2010  
197
Microglia activation and anti-inflammatory regulation in Alzheimer's disease.
[20195797] Mol Neurobiol 41(2-3): 115-28 (2010)
2010  
198
Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease.
[20195796] Mol Neurobiol 41(2-3): 73-86 (2010)
2010  
199
Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?
[20101529] Mol Neurobiol 41(2-3): 87-96 (2010)
2010  
200
The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.
[20052565] Mol Neurobiol 41(2-3): 97-106 (2010)
2011  
201
Mitochondrial quality control and Parkinson's disease: a pathway unfolds.
[21120708] Mol Neurobiol 43(2): 80-6 (2011)
2010  
202
Why pleiotropic interventions are needed for Alzheimer's disease.
[20437209] Mol Neurobiol 41(2-3): 392-409 (2010)
2009  
203
Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?
[19481107] Neurosci Biobehav Rev 33(7): 1099-108 (2009)
2008  
204
Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration.
[18180036] Neurosci Biobehav Rev 32(4): 693-706 (2008)
2010  
205
Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
[20661410] Int J Clin Exp Pathol 3(6): 618-28 (2010)
2010  
206
Alzheimer's disease: diverse aspects of mitochondrial malfunctioning.
[20661404] Int J Clin Exp Pathol 3(6): 570-81 (2010)
2008  
207
Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.
[18784819] Int J Clin Exp Pathol 1(1): 5-18 (2008)
2010  
208
Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter.
[20190429] Chem Pharm Bull (Tokyo) 58(3): 273-87 (2010)
2010  
209
Blood-based biomarkers of microvascular pathology in Alzheimer's disease.
[19782124] Exp Gerontol 45(1): 75-9 (2010)
2010  
210
Total and phosphorylated tau protein as biological markers of Alzheimer's disease.
[19853650] Exp Gerontol 45(1): 30-40 (2010)
2010  
211
Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease.
[19699791] Exp Gerontol 45(1): 57-63 (2010)
2010  
212
Inflammation and anti-inflammatory strategies for Alzheimer's disease--a mini-review.
[19752507] Gerontology 56(1): 3-14 (2010)
2010  
213
Relationship between tau pathology and neuroinflammation in Alzheimer's disease.
[20101714] Mt Sinai J Med 77(1): 50-8 (2010)
2010  
214
Current treatment and recent clinical research in Alzheimer's disease.
[20101716] Mt Sinai J Med 77(1): 3-16 (2010)
2010  
215
Role of vascular risk factors and vascular dysfunction in Alzheimer's disease.
[20101718] Mt Sinai J Med 77(1): 82-102 (2010)
2010  
216
Vaccination as a therapeutic approach to Alzheimer's disease.
[20101719] Mt Sinai J Med 77(1): 17-31 (2010)
2010  
217
Neuropathology of Alzheimer's disease.
[20101720] Mt Sinai J Med 77(1): 32-42 (2010)
2010  
218
Transgenic mouse models of Alzheimer's disease.
[20101721] Mt Sinai J Med 77(1): 69-81 (2010)
2010  
219
Cell "self-eating" (autophagy) mechanism in Alzheimer's disease.
[20101724] Mt Sinai J Med 77(1): 59-68 (2010)
2010  
220
Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies.
[20139660] Tohoku J Exp Med 220(2): 95-106 (2010)
2010  
221
Novel therapeutics for Alzheimer's disease: an update.
[20205057] Curr Opin Drug Discov Devel 13(2): 235-46 (2010)
2008  
222
Aluminum as a risk factor for Alzheimer's disease.
[18392545] Rev Lat Am Enfermagem 16(1): 151-7 (2008)
2011  
223
Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease.
[21439035] J Neuroinflammation 8(-): 26 (2011)
2011  
224
Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria.
[21816039] J Neuroinflammation 8(-): 90 (2011)
2008  
225
Interactions between APP secretases and inflammatory mediators.
[18564425] J Neuroinflammation 5(-): 25 (2008)
2008  
226
Alzheimer disease pathology as a host response.
[18520771] J Neuropathol Exp Neurol 67(6): 523-31 (2008)
2010  
227
Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration.
[20607039] Int J Clin Exp Med 3(2): 129-43 (2010)
2008  
228
Antioxidant therapy in Alzheimer's disease: theory and practice.
[18991755] Mini Rev Med Chem 8(13): 1395-406 (2008)
2009  
229
Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment.
[19847044] Behav Neurol 21(1): 39-49 (2009)
2009  
230
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.
[19847050] Behav Neurol 21(1): 117-28 (2009)
2011  
231
The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.
[22110363] Exp Neurobiol 20(2): 67-80 (2011)
2008  
232
Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies.
[18498669] Int Psychogeriatr 20(5): 871-89 (2008)
2005  
233
Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression.
[16306243] J Geriatr Psychiatry Neurol 18(4): 218-23 (2005)
2010  
234
Sequence variation in SORL1 and dementia risk in Swedes.
[19653016] Neurogenetics 11(1): 139-42 (2010)
2009  
235
Genetic aspects of Alzheimer disease.
[19276785] Neurologist 15(2): 80-6 (2009)
2008  
236
Biomarkers for early detection of Alzheimer pathology.
[18097155] Neurosignals 16(1): 11-8 (2008)
2005  
237
Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.
[15960984] Brain Res Brain Res Rev 49(1): 1-21 (2005)
2007  
238
Mechanisms of disease: new therapeutic strategies for Alzheimer's disease--targeting APP processing in lipid rafts.
[17611486] Nat Clin Pract Neurol 3(7): 374-82 (2007)
2009  
239
Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease.
[19114068] Neurochem Int 54(2): 84-8 (2009)
2010  
240
Early detection of Alzheimer's disease with PET imaging.
[20197691] Neurodegener Dis 7(1-3): 131-5 (2010)
2010  
241
2010  
242
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
[19815015] Exp Neurol 223(2): 334-46 (2010)
2010  
243
Signaling effect of amyloid-beta(42) on the processing of AbetaPP.
[19747481] Exp Neurol 221(1): 18-25 (2010)
2010  
244
Alzheimer's disease and tauopathy studies in flies and worms.
[20302939] Neurobiol Dis 40(1): 21-8 (2010)
2009  
245
Biomarkers of Alzheimer's disease.
[19010417] Neurobiol Dis 35(2): 128-40 (2009)
2010  
246
Probing the biology of Alzheimer's disease in mice.
[20547123] Neuron 66(5): 631-45 (2010)
2010  
247
Biomarkers in translational research of Alzheimer's disease.
[20394760] Neuropharmacology 59(4-5): 310-22 (2010)
2007  
248
Use of functional magnetic resonance imaging in the early identification of Alzheimer's disease.
[17476598] Neuropsychol Rev 17(2): 127-43 (2007)
2008  
249
Neuropsychological contributions to the early identification of Alzheimer's disease.
[18347989] Neuropsychol Rev 18(1): 73-90 (2008)
2008  
250
Defining "prodromal" Alzheimer's disease, frontotemporal dementia, and Lewy body dementia: are we there yet?
[18327642] Neuropsychol Rev 18(1): 70-2 (2008)
2010  
251
Alzheimer's disease and neuronal network activity.
[19885650] Neuromolecular Med 12(1): 44-7 (2010)
2010  
252
Adverse stress, hippocampal networks, and Alzheimer's disease.
[19943124] Neuromolecular Med 12(1): 56-70 (2010)
2010  
253
Functional alterations in memory networks in early Alzheimer's disease.
[20069392] Neuromolecular Med 12(1): 27-43 (2010)
2010  
254
An overview of APP processing enzymes and products.
[20232515] Neuromolecular Med 12(1): 1-12 (2010)
2005  
255
Transgenic models of Alzheimer's disease: learning from animals.
[16389306] NeuroRx 2(3): 423-37 (2005)
2005  
256
APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder.
[15744222] CNS Spectr 10(3): 207-22 (2005)
2009  
257
Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer's disease.
[19890241] CNS Spectr 14(8 Suppl 7): 8-13; discussion 16-8 (2009)
2010  
258
Discovery of notch-sparing gamma-secretase inhibitors.
[20088802] Curr Alzheimer Res 7(3): 207-9 (2010)
2009  
259
Towards retinoid therapy for Alzheimer's disease.
[19519313] Curr Alzheimer Res 6(3): 302-11 (2009)
2008  
260
Gamma-secretase inhibition and modulation for Alzheimer's disease.
[18393800] Curr Alzheimer Res 5(2): 158-64 (2008)
2008  
261
Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease.
[18393798] Curr Alzheimer Res 5(2): 132-46 (2008)
2008  
262
Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.
[18537546] Curr Alzheimer Res 5(3): 319-41 (2008)
2008  
263
The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease.
[18713574] Curr Neurol Neurosci Rep 8(5): 384-91 (2008)
2009  
264
Update on amyloid imaging: from healthy aging to Alzheimer's disease.
[19664363] Curr Neurol Neurosci Rep 9(5): 345-52 (2009)
2009  
265
2011  
266
Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.
[21649911] Mol Brain 4(1): 23 (2011)
2011  
267
APP processing in Alzheimer's disease.
[21214928] Mol Brain 4(-): 3 (2011)
2010  
268
Presenilins and the gamma-secretase: still a complex problem.
[20181106] Mol Brain 3(-): 7 (2010)
2011  
269
Biology and pathophysiology of the amyloid precursor protein.
[21527012] Mol Neurodegener 6(1): 27 (2011)
2011  
270
Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease.
[21569597] Mol Neurodegener 6(-): 31 (2011)
2007  
271
The Alzheimer's disease beta-secretase enzyme, BACE1.
[18005427] Mol Neurodegener 2(-): 22 (2007)
2011  
272
Biomarkers in Alzheimer's disease.
[21808632] Front Neurol 2(-): 46 (2011)
2011  
273
Biomarkers predicting Alzheimer's disease in cognitively normal aging.
[21779293] J Clin Neurol 7(2): 60-8 (2011)
2010  
274
The clinical use of structural MRI in Alzheimer disease.
[20139996] Nat Rev Neurol 6(2): 67-77 (2010)
2010  
275
The secretases: enzymes with therapeutic potential in Alzheimer disease.
[20139999] Nat Rev Neurol 6(2): 99-107 (2010)
2005  
276
Genetic mouse models of Alzheimer's disease.
[16444901] Neural Plast 12(4): 299-310 (2005)
2007  
277
The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.
[16944319] Neurochem Res 32(4-5): 609-23 (2007)
2007  
278
Alzheimer's disease and mild cognitive impairment.
[17659182] Neurol Clin 25(3): 577-609, v (2007)
2007  
279
An update on the amyloid hypothesis.
[17659184] Neurol Clin 25(3): 669-82, vi (2007)
2010  
280
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
[20205639] CNS Neurol Disord Drug Targets 9(2): 207-16 (2010)
2010  
281
Amyloid-beta immunotherapy for Alzheimer's disease.
[20205640] CNS Neurol Disord Drug Targets 9(2): 197-206 (2010)
2009  
282
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.
[19275636] CNS Neurol Disord Drug Targets 8(1): 50-64 (2009)
2009  
283
Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.
[19355930] CNS Neurol Disord Drug Targets 8(2): 88-97 (2009)
2009  
284
Alternative Abeta immunotherapy approaches for Alzheimer's disease.
[19355932] CNS Neurol Disord Drug Targets 8(2): 114-27 (2009)
2008  
285
Beta-secretase: structure, function, and evolution.
[18673212] CNS Neurol Disord Drug Targets 7(3): 278-94 (2008)
2011  
286
Combined Imaging Markers Dissociate Alzheimer's Disease and Frontotemporal Lobar Degeneration - An ALE Meta-Analysis.
[21811457] Front Aging Neurosci 3(-): 10 (2011)
2010  
287
Staging anti-inflammatory therapy in Alzheimer's disease.
[21152343] Front Aging Neurosci 2(-): 142 (2010)
2010  
288
Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease.
[20552046] Front Aging Neurosci 2(-): 8 (2010)
2010  
289
Presenilin/gamma-Secretase and Inflammation.
[20559464] Front Aging Neurosci 2(-): 16 (2010)
2011  
290
Membrane Incorporation, Channel Formation, and Disruption of Calcium Homeostasis by Alzheimer's β-Amyloid Protein.
[21547225] Int J Alzheimers Dis 2011(-): 304583 (2011)
2011  
291
The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations.
[21423560] Int J Alzheimers Dis 2011(-): 726197 (2011)
2011  
292
Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts.
[21331330] Int J Alzheimers Dis 2011(-): 906964 (2011)
2011  
293
Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease.
[22114742] Int J Alzheimers Dis 2011(-): 151645 (2011)
2011  
294
Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications.
[22114743] Int J Alzheimers Dis 2011(-): 517160 (2011)
2008  
295
Targeting the endocannabinoid system in Alzheimer's disease.
[18997302] J Alzheimers Dis 15(3): 495-504 (2008)
2010  
296
A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease.
[20463393] J Alzheimers Dis 20 Suppl 2(-): S401-12 (2010)
2010  
297
Neuropathologic alterations in mild cognitive impairment: a review.
[20061641] J Alzheimers Dis 19(1): 221-8 (2010)
2010  
298
Alzheimer's disease and the amyloid-beta peptide.
[20061647] J Alzheimers Dis 19(1): 311-23 (2010)
2008  
299
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
[18953105] J Alzheimers Dis 15(2): 157-68 (2008)
2008  
300
Chronic inflammation and amyloidogenesis in Alzheimer's disease -- role of Spirochetes.
[18487847] J Alzheimers Dis 13(4): 381-91 (2008)
2008  
301
The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective.
[19098445] Prion 2(2): 51-6 (2008)
2009  
302
Prion protein and Alzheimer disease.
[19887909] Prion 3(4): 190-4 (2009)
2010  
303
Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker?
[21034526] BMB Rep 43(10): 649-55 (2010)
2011  
304
Biomarkers in Alzheimer's disease.
[21303300] Clin Chem Lab Med 49(5): 773-8 (2011)
2009  
305
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.
[19829371] Nature 461(7266): 916-22 (2009)
2010  
306
2010  
307
Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.
[19960174] J Mol Med (Berl) 88(4): 331-8 (2010)
2008  
308
Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.
[18486927] Autoimmun Rev 7(5): 391-7 (2008)
2008  
309
Copper binding to the Alzheimer's disease amyloid precursor protein.
[18030462] Eur Biophys J 37(3): 269-79 (2008)
2009  
310
Cytoskeletal pathologies of Alzheimer disease.
[19479823] Cell Motil Cytoskeleton 66(8): 635-49 (2009)
2009  
311
New strategies for Alzheimer's disease and cognitive impairment.
[20716915] Oxid Med Cell Longev 2(5): 279-89 (2009)
2011  
312
Identifying and validating biomarkers for Alzheimer's disease.
[20971518] Trends Biotechnol 29(1): 26-32 (2011)
2008  
313
Genetic aspects of Alzheimer disease.
[18414205] Genet Med 10(4): 231-9 (2008)
2010  
314
2010  
315
Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain.
[20854368] J Neurochem 115(5): 1077-89 (2010)
2010  
316
Yeast as a model for studying Alzheimer's disease.
[20618869] FEMS Yeast Res 10(8): 961-9 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Demenzen


  • Search PubMed and many other databases on the combined search terms

    GG: alzheimer disease
    GG: alzheimer's disease

  • Alzheimer Erkrankung

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia